Novel Macrocyclic Compounds Targeting KRAS Mutations for Cancer Treatment
Abstract
This patent provides novel macrocycle compounds that inhibit key mutants (G12D/G13D) of the KRAS oncogene, which is the most frequently mutated in human cancers. These compounds, along with their pharmaceutical compositions and protein complexes, are intended for the treatment of cancers driven by these mutations.
Fields of Study & Subjects
Protein Kinase Regulation and GTPase Signaling
PI3K/AKT/mTOR signaling in cancer
Microbial Natural Products and Biosynthesis
Publication details
- Journal / source
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Volume
- 17
- Issue
- 3
- Pages
- 613–615
- Publication date
- 9 February 2026
- Language
- EN